Curated News
By: NewsRamp Editorial Staff
November 17, 2026
Sino Biological Launches AI-Trusted and AI-Qualified Protein Collections
TLDR
- Sino Biological's AI-Trusted and AI-Qualified protein collections give researchers a validated, ready-to-use advantage in AI-driven discovery.
- Sino Biological's collections provide experimentally characterized proteins with binding data, supported by a 4S system for scale, scope, speed, and supply.
- Sino Biological's target protein collections aim to accelerate therapeutic and diagnostic development, potentially improving health outcomes worldwide.
- Sino Biological offers over 11,000 recombinant target proteins, including 1,200 biotinylated proteins, for diverse AI research applications.
Impact - Why it Matters
The introduction of these specialized protein collections addresses a critical bottleneck in AI-driven drug discovery: the availability of high-quality, well-characterized target proteins for experimental validation. As AI increasingly designs novel proteins and antibodies, researchers need reliable reagents to test these designs in the lab. Sino Biological's collections, backed by the 4S System, provide the scale, scope, speed, and supply reliability necessary to support AI research programs. By offering proteins with demonstrated use in AI projects and characterized binding activity, the company empowers researchers to bridge the gap between computational predictions and experimental evidence, potentially accelerating the development of new therapeutics and diagnostics. This matters because it enables faster, more informed decisions in drug discovery, ultimately bringing innovative treatments to patients sooner.
Summary
Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global biotechnology company specializing in recombinant proteins, antibodies, and CRO services, has launched two dedicated target protein collections to support AI-driven discovery: AI-Trusted Proteins and AI-Qualified Proteins. These collections address the growing need for well-characterized proteins to evaluate AI-designed molecules in therapeutic and diagnostic development. The AI-Trusted Proteins collection includes over 600 targets and 960 individual proteins that have been used in AI-focused company validation projects, with some featured in published research. Each protein comes with characterization data such as SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS. The AI-Qualified Proteins collection offers more than 680 targets and 1,700 individual proteins, each experimentally characterized for target binding activity, including SPR/BLI validation data, and includes specialized formats like biotinylated proteins. Both collections are backed by Sino Biological's 4S System—Scale, Scope, Speed, and Supply—which provides access to over 11,000 recombinant target proteins, including more than 1,200 biotinylated proteins, broad coverage of protein types, rapid production, and reliable supply. Additionally, the company offers a therapeutic target directory covering 12 therapeutic areas and over 100 diseases. These target proteins are a key component of Sino Biological's 4RISE™ AI Lab Validation Solution, which integrates high-throughput protein expression, binding and affinity characterization, developability assessment, and functional validation to help researchers advance AI-designed molecules from computational predictions to experimental evidence. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized that AI-driven discovery depends on reliable experimental resources, and the combination of AI-Trusted and AI-Qualified proteins with the 4S System aims to provide researchers with well-characterized targets, broad coverage, and dependable supply.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Sino Biological Launches AI-Trusted and AI-Qualified Protein Collections
